| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/04/2001 | WO2001000169A1 Cosmetic compositions |
| 01/04/2001 | WO2001000168A1 Cosmetic compositions |
| 01/04/2001 | WO2001000167A1 Cosmetic compositions containing vitamin b¿3? |
| 01/04/2001 | WO2001000166A1 Cosmetic compositions containing pantothenic acid |
| 01/04/2001 | WO2001000165A1 Cosmetic compositions containing a quaternary ammonium compound and tocopherol |
| 01/04/2001 | WO2001000164A1 Cosmetic compositions containing vitamin b3 |
| 01/04/2001 | WO2001000163A1 Cosmetic method |
| 01/04/2001 | WO2001000162A1 Cosmetic compositions containing vitamin b3 |
| 01/04/2001 | WO2001000161A1 Cosmetic compositions |
| 01/04/2001 | WO2001000160A1 Cosmetic compositions containing vitamin b3 |
| 01/04/2001 | WO2001000159A1 Cosmetic compositions containing vitamin b3 |
| 01/04/2001 | WO2001000158A1 Cosmetic compositions containing quaternary ammonium compounds |
| 01/04/2001 | WO2001000153A1 Process and composition for temporarily suppressing pain |
| 01/04/2001 | WO2001000151A1 Topical anti-microbial compositions |
| 01/04/2001 | WO2001000147A1 Cosmetic compositions |
| 01/04/2001 | WO2001000146A1 Cosmetic compositions |
| 01/04/2001 | WO2001000145A1 Method for scavenging radicals with urocanic acid, derivatives and analogues |
| 01/04/2001 | WO2001000139A1 Topical formulations comprising skin penetration agents and the use thereof |
| 01/04/2001 | WO2001000138A2 Use of hydroxydiphenyl ether class of chemicals, as exemplified by triclosan, as an antimalarial and identification of fatty acid synthesis as its target |
| 01/04/2001 | WO2001000082A1 Imaging the dopamine transporter to determine ad-hd |
| 01/04/2001 | WO2001000047A1 Prophylactic dietary supplement based on milk |
| 01/04/2001 | WO2001000046A1 Use of nanoscale sterols and sterol esters |
| 01/04/2001 | WO2001000045A1 Drinks and foods capable of eliminating helicobacter pylori |
| 01/04/2001 | WO2001000044A1 Novel chitosan-containing liquid compositions and methods for their preparation and use |
| 01/04/2001 | WO2001000021A1 Pyrithione biocides enhanced by silver, copper, or zinc ions |
| 01/04/2001 | WO2000062769A3 Use of ap-1 activators to treat glaucoma and ocular hypertension |
| 01/04/2001 | WO2000061069A3 Methods and compositions for use in the treatment of hyperlipidemia |
| 01/04/2001 | WO2000059449A3 Purine derivatives having phosphodiesterase iv inhibition activity |
| 01/04/2001 | WO2000058455A3 Methods for the identification and validation of functional intracellular targets with intramers or in vivo selection |
| 01/04/2001 | WO2000056405A3 Human tumor necrosis factor receptor-like 2 |
| 01/04/2001 | WO2000056300A3 Synthesis and structure of metallocene compounds and their interactions with lipid membranes |
| 01/04/2001 | WO2000051684A3 Regulators of coenzyme-a-independent transacylase as psychotropic drugs |
| 01/04/2001 | WO2000051578A3 Use of ceramides for the treatment of cystic fibrosis |
| 01/04/2001 | WO2000044761A3 Ketolide antibiotics |
| 01/04/2001 | WO2000039302A3 Improved expression of hiv polypeptides and production of virus-like particles |
| 01/04/2001 | WO2000038715A3 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 01/04/2001 | WO2000031095A3 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 01/04/2001 | WO2000029438A9 Egf-like nucleic acids and polypeptides and uses thereof |
| 01/04/2001 | WO2000021516A3 Methods for inhibiting diabetic complications |
| 01/04/2001 | WO2000020358B1 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION |
| 01/04/2001 | WO2000000161A3 Methods for identification of tef-3 interacting factors |
| 01/04/2001 | WO1999062451A8 Topical transdermal treatments |
| 01/04/2001 | DE19930454A1 Feste Paroxetin enthaltende Zubereitungen Solid preparations containing paroxetine |
| 01/04/2001 | DE19929785A1 Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung Tetrahydroquinolinyl-6-methyldihydrothiadiazinon derivatives and their use |
| 01/04/2001 | DE19929782A1 6-Carboxyphenyldihydropyridazinon-Derivate und ihre Verwendung 6-Carboxyphenyldihydropyridazinon derivatives and their use |
| 01/04/2001 | DE19929361A1 Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen Mechanically stable pharmaceutical dosage forms containing liquid or semisolid surface-active substances |
| 01/04/2001 | CA2727172A1 Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| 01/04/2001 | CA2385798A1 Substituted phenoxyacetic acids |
| 01/04/2001 | CA2383546A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2380873A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/04/2001 | CA2378227A1 Antisense modulation of pi3k p85 expression |
| 01/04/2001 | CA2377721A1 Sgip peptides |
| 01/04/2001 | CA2377492A1 Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease |
| 01/04/2001 | CA2377437A1 Antisense modulation of ship-2 expression |
| 01/04/2001 | CA2377287A1 Preparation of substituted cyclopentane and cyclopentene compounds and certain intermediates |
| 01/04/2001 | CA2377273A1 Antisense oligonucleotide modulating cyclin e gene expression and therapeutic uses thereof |
| 01/04/2001 | CA2377272A1 Triazole compounds and combinatorial libraries thereof |
| 01/04/2001 | CA2377211A1 Copolymers for transporting nucleic acids in the cell |
| 01/04/2001 | CA2377207A1 Combinations for introducing nucleic acids into cells |
| 01/04/2001 | CA2377200A1 Pyrazolidinol compounds |
| 01/04/2001 | CA2377186A1 Novel fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof |
| 01/04/2001 | CA2377163A1 Screening methods for compounds that affect melanogenesis |
| 01/04/2001 | CA2377154A1 Novel quaternary ammonium derivatives, method for preparing same and pharmaceutical use |
| 01/04/2001 | CA2377141A1 Curcumin and curcuminoid inhibition of angiogenesis |
| 01/04/2001 | CA2377132A1 Amorphous nitric esters and their pharmaceutical compositions |
| 01/04/2001 | CA2377117A1 6-carboxyphenyldihydropyridazinone derivatives and use thereof |
| 01/04/2001 | CA2377087A1 Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containing the same |
| 01/04/2001 | CA2377086A1 Self-emulsifying systems containing anticancer medicament |
| 01/04/2001 | CA2377074A1 Method for preparing polycation based bioconjugates suitable for transporting different kinds of active substances within the body |
| 01/04/2001 | CA2376957A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2376951A1 Src kinase inhibitor compounds |
| 01/04/2001 | CA2376938A1 Medicinal compositions for preventing or treating diarrhea |
| 01/04/2001 | CA2376922A1 Compounds obtained from salvia species having antiviral activity |
| 01/04/2001 | CA2376920A1 Method for preventing tumoral growth |
| 01/04/2001 | CA2376892A1 Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
| 01/04/2001 | CA2376891A1 Tetrahydroquinolinyl-6-methyldihydrothiadiazinone derivatives and use thereof |
| 01/04/2001 | CA2376888A1 Cosmetic compositions |
| 01/04/2001 | CA2376886A1 Therapeutic agents |
| 01/04/2001 | CA2376881A1 Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments |
| 01/04/2001 | CA2376842A1 Cosmetic compositions |
| 01/04/2001 | CA2376840A1 Cosmetic compositions containing pantothenic acid |
| 01/04/2001 | CA2376838A1 Cosmetic compositions containing a quaternary ammonium compound and tocopherol |
| 01/04/2001 | CA2376818A1 Use of nanoscale sterols and sterol esters |
| 01/04/2001 | CA2376817A1 Cosmetic method |
| 01/04/2001 | CA2376807A1 Cosmetic compositions |
| 01/04/2001 | CA2376785A1 Benzimidazoles and imidazopyridines as respiratory syncytial virus replication inhibitors |
| 01/04/2001 | CA2376781A1 Benzimidazoles and imidazopyridines as respiratory syncytial virus replication inhibitors |
| 01/04/2001 | CA2376758A1 Hexahydropyrrolo¬1,2-c|pyrimidines as antiviral, antifungal and/or antitumor agents |
| 01/04/2001 | CA2376714A1 Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers |
| 01/04/2001 | CA2376307A1 Novel piperazinylalkylthiopyrimidine derivatives,pharmaceutical composi tions containing the same,and a process for the preparation of the active substance |
| 01/04/2001 | CA2376213A1 Therapeutic agents |
| 01/04/2001 | CA2376023A1 Therapeutic agents |
| 01/04/2001 | CA2375972A1 Pharmaceutical composition containing sibutramine and orlistat |
| 01/04/2001 | CA2375952A1 Reverse-turn mimetics and methods relating thereto |
| 01/04/2001 | CA2375852A1 Zinc ionophores as anti-apoptotic agents |
| 01/04/2001 | CA2374610A1 Catalytically active recombinant memapsin and methods of use thereof |
| 01/04/2001 | CA2370517A1 Stabilized viral envelope proteins and uses thereof |
| 01/04/2001 | CA2370500A1 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof |
| 01/04/2001 | CA2369839A1 Compositions of insulin and insulin-related peptide for treating diabetes |
| 01/04/2001 | CA2369308A1 Vla-4 inhibitor compounds |